ProCE Banner Activity

Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access

Slideset

Download these slides to see recent updates on the use of immunotherapy in MM, including optimizing CD38 monoclonal antibody therapy in the first-line setting and current data on BCMA-targeted agents after progression.

Released: May 17, 2024

Expiration: May 16, 2025

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center 9500 Euclid Avenue CA-6
Cleveland, Ohio

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner